Two projects from Pathology & Immunology were selected this year to receive funding though the Leadership in Entrepreneurial Acceleration Program (LEAP). They include:
Targeting type III interferon for the treatment of multiple sclerosis
This project is a potential new biomarker of progressive forms of multiple sclerosis (MS) that, when targeted, can prevent axonal injury and disease progression from autoimmune attack of the brain and spinal cord in an animal model of MS.
Management: Robyn S. Klein, MD, PhD, Vice Provost; Associate Dean for Graduate Education; Division of Biology and Biomedical Sciences; Director, Center for Neuroimmunology & Neuroinfectious Diseases; Professor of Medicine, Pathology & Immunology, Neuroscience
Re-inventing Arterial Blood Gas Measurements
This project is a new medical device that performs laboratory tests without needing to draw blood.
Management: Abraham Qavi, MD, PhD, PSTP, Clinical Pathology and Lan Yang, MS, PhD, Edwin H. & Florence G. Skinner Professor, School of Engineering and Applied Science
Registration is open for the next LEAP cycle
Register by 2/28 here.